What question did this study set out to answer?

The aim is to summarize the milestones leading to the first approval of decitabine/cedazuridine for MDS and CMML treatment.

August 29, 2020DrugsOpen Access

Decitabine/Cedazuridine: First Approval

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial demonstrates efficacy of decitabine/cedazuridine in myelodysplastic syndromes, indicating significant treatment advancement.

The aim is to summarize the milestones leading to the first approval of decitabine/cedazuridine for MDS and CMML treatment.
Examined the development of decitabine and cedazuridine combination in clinical settings.
Analyzed the drug's mechanism as a DNA methyltransferase inhibitor and its enhanced bioavailability.
Reviewed regulatory milestones leading up to the approval in the USA and Canada.
Decitabine/cedazuridine received approval in July 2020 for MDS and CMML treatment.
Increased oral bioavailability of decitabine when combined with cedazuridine was confirmed.
Ongoing clinical studies are investigating efficacy in AML, gliomas, and solid tumors.

Sohita Dhillon (2020) studied this question.

View Full Paper

Ask AI

Bookmark

Randomized trial demonstrates efficacy of decitabine/cedazuridine in myelodysplastic syndromes, indicating significant treatment advancement.